Get to know our clinical trials

Phase 3 clinical trial to evaluate the safety and efficacy of epcoritamab rituximab and lenalidomide (R2).

THE AIM OF THIS STUDY IS TO SEE IF THE COMBINATION OF THE STUDY DRUG EPCORITAMAB WITH RITUXIMAB AND LENALIDOMIDE HAS A BETTER RESPONSE RATE THAN STANDARD CHEMOIMMUNOTHERAPY IN THE TREATMENT OF FOLLICULAR LYMPHOMA.

Imagen del Dr. Carlos Grande García, especialista en Hematología y Hemoterapia de la Clínica Universidad de Navarra.
Dr. Carlos García Grande Curriculum
Specialist Hematology and Hemotherapy Department
Madrid headquarters
Cancer Center
Hematologic Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF EPCORITAMAB RITUXIMAB AND LENALIDOMIDE (R2) COMPARED TO CHEMOIMMUNOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (EPCORE¿FL-2). IMMUNOTHERAPY
  • Code EudraCT: 2023-506906-38-00
  • Protocol number: M22-003
  • Promoter: Abbvie Spain SLU
  • Molecule/Drug: Epcoritamab Rituximab y Lenalidomida

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION